SEARCH

SEARCH BY CITATION

References

  • Ahlke, E., Nowak-Gottl, U., Schulze-Westhoff, P., Werber, G., Borste, H., Wurthwein, G., Jurgens, H. & Boos, J. (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 96, 675681.
  • Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J. & Garratty, G. (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 110, 103111.
  • Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. & Cohen, H.J. (1993) Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical Oncology, 11, 17801786.
  • Avramis, V.I. & Panosyan, E.H. (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clinical Pharmacokinetics, 44, 367393.
  • Avramis, V.I. & Spence, S.A. (2007) Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. Journal of Pediatric Hematology/Oncology, 29, 239247.
  • Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, B.C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., Hilden, J.M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., Holcenberg, J.S. & Stork, L. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood, 99, 19861994.
  • Boos, J., Nowak-Gottl, U., Jurgens, H., Fleischhack, G. & Bode, U. (1995) Loss of activity of Erwinia asparaginase on repeat applications. Journal of Clinical Oncology, 13, 24742475.
  • Chatelut, E., Boddy, A.V., Peng, B., Rubie, H., Lavit, M., Dezeuze, A., Pearson, A.D., Roche, H., Robert, A., Newell, D.R. & Canal, P. (1996) Population pharmacokinetics of carboplatin in children. Clinical Pharmacology and Therapeutics, 59, 436443.
  • Hill, J.M., Roberts, J., Loeb, E., Khan, A., MacLellan, A. & Hill, R.W. (1967) l-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. Journal of the American Medical Association, 202, 882888.
  • Hill, J.M., Loeb, E., MacLellan, A., Khan, A., Roberts, J., Shields, W.F. & Hill, N.O. (1969) Response to highly purified l-asparaginase during therapy of acute leukemia. Cancer Research, 29, 15741580.
  • Ho, D.H., Brown, N.S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R.A. & Krakoff, I.H. (1986) Clinical pharmacology of polyethylene glycol-l-asparaginase. Drug Metabolism and Disposition, 14, 349352.
  • Karlsson, M.O. & Sheiner, L.B. (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. Journal of Pharmacokinetics and Biopharmaceutics, 21, 735750.
  • Lanvers, C., Vieira Pinheiro, J.P., Hempel, G., Wuerthwein, G. & Boos, J. (2002) Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum. Analytical Biochemistry, 309, 117126.
  • Muller, H.J. & Boos, J. (1998) Use of l-asparaginase in childhood ALL. Critical Reviews in Oncology/Hematology, 28, 97113.
  • Muller, H.J., Loning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Von, S.V., Henze, G., Casimiro, D.P., Ritter, J., Pinheiro, J.P., Winkelhorst, M. & Boos, J. (2000) Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology, 110, 379384.
  • Muller, H.J., Beier, R., Da Palma, J.C., Lanvers, C., Ahlke, E., Von, S.V., Gunkel, M., Horn, A., Schrappe, M., Henze, G., Kranz, K. & Boos, J. (2002) PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemotherapy and Pharmacology, 49, 149154.
  • Raes, A., Van Aken, S., Craen, M., Donckerwolcke, R. & Vande, W.J. (2006) A reference frame for blood volume in children and adolescents. BMC Pediatrics, 6, 3.
  • Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H. & Poplack, D.G. (1981) l-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Research, 41, 45544558.
  • Vieira Pinheiro, J.P., Lanversa, C., Wurthwein, G., Beier, R., Casimiro, D.P., Von Stackelberg, A. & Boos, J. (2002) Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Leukemia & Lymphoma, 43, 19111920.
  • Wenner, K.A., Vieira Pinheiro, J.P., Escherich, G., Wessalowski, R., Jorch, N., Wolff, J., Stehn, M., Kohlschutter, A., Boos, J. & Janka-Schaub, G.E. (2005) Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klinische Pädiatrie, 217, 321326.